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Abstract
Liver transplant candidates and recipients with hepatitis 
C virus (HCV)-related liver disease greatly benefit from 
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an effective antiviral therapy. The achievement of a 
sustained virological response before transplantation 
can prevent the recurrence of post-transplant HCV 
disease that occurs universally and correlates with 
enhanced progression to graft cirrhosis. Previous 
standard-of-care regimens (e.g. , pegylated-interferon 
plus ribavirin with or without first generation protease 
inhibitors, boceprevir and telaprevir) displayed 
suboptimal results and poor tolerance in liver transplant 
recipients. A new class of potent direct-acting antiviral 
agents (DAA) characterized by all-oral regimens with 
minimal side effects has been approved and included 
in the recent guidelines for the treatment of liver 
transplant recipients with recurrent HCV disease. 
Association of sofosbuvir with ribavirin and/or ledipasvir 
is recommended in liver transplant recipients and 
patients with decompensated cirrhosis. Other regimens 
include simeprevir, daclatasvir, and combination of 
other DAA. Possible interactions should be monitored, 
especially in coinfected human immunodeficiency virus/
HCV patients receiving antiretrovirals.
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Core tip: Until recently, a well-tolerated and effective 
treatment protocol to address the recurrence of 
hepatitis C virus (HCV) infection following liver 
transplantation has been an important unmet clinical 
need. Safe and effective treatment options are now 
available thanks to the approval of new classes of 
direct antiviral agents. The aim of this review was to 
summarize the outcome of previous treatments and 
discuss the impact of current options for the treatment 
of HCV among liver transplantation candidates and 
recipients, including coinfected human immuno-
deficiency virus/HCV patients.
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INTRODUCTION
An estimated 130 to 170 million people are infected 
with hepatitis C virus (HCV) worldwide, and an 
additional 3 to 4 million are newly infected each year[1]. 
The epidemiology and burden of HCV infection vary 
geographically, with prevalence rates ranging from < 
1% to > 10%[2]. Overall, around 25% of all cases of 
cirrhosis and HCC are related to HCV, with significantly 
higher rates among countries that have a high 
prevalence of the disease[3]. Chronic HCV infection is 
associated with substantial mortality, with over 350000 
deaths per year attributed to HCV-related cirrhosis and 
hepatocellular carcinoma (HCC)[4-6]. The development 
of cirrhosis and HCC due to HCV infection represents 
the most common indication for liver transplantation 
(LT) in the United States, accounting for around 
40% of all cases on the United States waiting list[7]. 
Furthermore, projections have identified a constant 
increase in the number of patients with HCV-related 
end-stage liver disease (ESLD) who will be listed for LT 
over the next 10 years[8,9]. In this patient population, 
transplantation is an effective treatment to reduce 
morbidity and mortality. HCV recurrence, however, 
is universal in liver transplant recipients (LTR). Since 
HCV disease is associated with accelerated graft loss 
and diminished patient survival, the availability of a 
safe and efficacious therapy is essential among LTR[10]. 
For this group of patients, the real challenge for HCV 
treatment starts after LT.
In the past, the use of HCV treatments including 
pegylated interferon (Peg-INF) and ribavirin (RBV), 
either alone or in association with first generation 
protease inhibitors (PI) such as telaprevir or boceprevir, 
was limited by suboptimal viral responses, drug-drug 
interactions, and the occurrence of severe side effects, 
some of which have caused graft loss or have been 
fatal[11]. The approval of highly effective new molecules 
(i.e., new wave NS3-4A PI, nucleotide analogues, 
NS5A inhibitors) has revolutionized the scenario for 
the treatment of HCV infection. Goals of the new anti-
HCV drugs include outcome improval, reduction of 
side effects and drug-drug interactions, and regimen 
simplification. As summarized in Table 1, newly anti-
HCV drugs are expected to optimize the treatment 
before LT, allowing patients to undergo transplantation 
with undetectable HCV viral load, and after LT, 
offering safe and broadly effective options to prevent 
recurrence of HCV infection.
To keep pace with the newest discoveries in the 
field of HCV treatment, the Infectious Diseases Society 
of America (IDSA) and the American Association for 
the Study of Liver Diseases (AASLD), in collaboration 
with the International Antiviral Society-United States 
(IAS-United States), created a website that allows to 
access updated, evidence-based recommendations for 
the management of HCV[12]. 
ANTI-HCV DRUGS: OLDER AND 
NEWER OPTIONS FOR PATIENTS WITH 
ADVANCED LIVER DISEASE
The goal of treatment in HCV infected individuals 
is the achievement of virologic cure (or sustained 
virological response, SVR), defined as the absence of 
detectable levels of HCV RNA (e.g., ≤ 25 IU/mL with 
an FDA approved nucleic acid test) at least 12 wk after 
completion of therapy (SVR12). In more than 99% 
of patients, SVR12 has been shown to be durable 
for 5 years or more[13]. Successful HCV treatment 
dramatically decreases hepatic decompensation 
events, HCC incidence, and liver-related mortality[14]. 
Furthermore, it has been demonstrated that patients 
with advanced fibrosis who achieve SVR have a 
decreased need for LT compared with patients who 
do not attain SVR[15]. Thus, prompt HCV treatment 
is prioritized for advanced liver disease, and urgent 
initiation is advocated in patients with severe 
extrahepatic HCV disease, significant fibrosis (Metavir 
F3-F4), decompensated cirrhosis (Child-Turcotte-Pugh 
B and C), and candidates or recipients of LT[16].
Interferon-ribavirin combination
Until recently, the combination of IFN or Peg-IFN and 
RBV has been considered the treatment of choice for 
patients with chronic HCV, including those progressing 
to cirrhosis. With this regimen, SVR can be achieved 
in 30%-40% and 70%-90% of patients with HCV 
genotype 1 vs genotypes 2 or 3, respectively[17-19]. 
Over the past two decades, modest efficacy along with 
a high incidence of serious adverse events (SAE) have 
characterized this treatment; furthermore, Peg-INF/
RBV optimal timing, dose, and duration in difficult-to-
treat populations requiring urgent treatment, such as 
patients with ESLD, have never been clearly defined. 
Boceprevir and telaprevir
In 2011, the first generation of direct-acting antivirals 
(DAA), boceprevir (BOC) and telaprevir (TVR), was 
approved for patients with genotype 1 HCV disease. 
BOC is a keto-amide serine PI that reversibly binds to 
the HCV nonstructural 3 (NS3) active site; TVR inhibits 
the NS3/4A HCV protease[20,21]. SVR with PI-based 
triple therapy (e.g., association of a PI with Peg-IFN/
RBV) reached 68%-75% in naïve and 59%-88% in 
experienced patients[22-25]. Due to the improved rate 
of SVR attainment for genotype 1 patients, the use of 
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BOC and TVR was initially included as standard-of-care 
for HCV infection[26]. However, these drugs still had 
to be associated with Peg-IFN/RBV and required long 
treatment duration (24-48 wk), causing an increase in 
treatment burden and side effects. For these reasons, 
BOC use is no more recommended and TVR has been 
removed from the market due to the development of 
more effective compounds[27,28]. 
DAA
More recently, clinical trials have shown revolutionary 
results in the treatment of HCV with the use of 
new DAA and their combination products, with and 
without Peg-IFN. Due to elevated SVR, good safety 
profiles, and once to twice daily administration, these 
compounds have now been incorporated into the 
AASLD/IDSA recommendations[12]. 
In December 2013, the United States Food and 
Drug Administration (FDA) approved sofosbuvir (SOF), 
a nucleotide polymerase inhibitor of NS5B targeting 
HCV-RNA replication[29]. SOF is metabolized in its active 
form that competes with the uridine triphosphate for 
incorporation into the growing HCV-RNA by the non-
structural protein 5B (NS5B) polymerase, acting as a 
chain terminator[30]. Since the NS5B active site is highly 
conserved across HCV genotypes, SOF displays a pan-
genotypic efficacy[31]. The administration of SOF 400 
mg once daily (OD) for 12 wk has been associated with 
rapid decrease of HCV-RNA and SVR above 85%, either 
in combination with Peg-IFN/RBV or with RBV alone as 
part of an IFN-free regimen[32,33]. Safety data has been 
promising also in advanced, decompensated cirrhosis 
showing discontinuation rates below 2% and few 
SAE[34]. Furthermore, low drug-drug interactions have 
been observed and no dose adjustments were required 
in patients with hepatic impairment[35]. Simeprevir 
(SMV, 150 mg OD), a second wave NS3/4A protease 
inhibitor, has been approved for use in combination 
with Peg-IFN/RBV in 2013 and, in November 2014, 
for the treatment of HCV genotype 1 in combination 
with SOF. IFN-free regimens containing SMV were 
also well-tolerated and showed overall SVR12 above 
90%[36]. The association of ledipasvir (LDV, 90 mg OD), 
a NS5A inhibitor, with SOF was approved by the FDA 
in November 2014 based on the results of large phase 
3 multicenter, open-label, randomized clinical trials 
showing SVR between 93% and 99%[37,38]. A four-
drug, twice daily combination regimen, consisting of 
75 mg of paritaprevir (a NS3/4A protease inhibitor), 
50 mg of ritonavir (a CYP3A inhibitor, used as a 
pharmacologic booster), and 12.5 mg of ombitasvir (a 
NS5A inhibitor), packaged with two 250 mg dasabuvir 
(a non-nucleoside NS5B polymerase inhibitor) tablets 
has also been approved by the FDA and studied in 
combination with RBV for genotype 1 patients[39-41]. 
Daclatasvir (DCV, 60 mg OD), a pan-genotypic NS5A 
inhibitor, was approved in Europe in August 2014 and is 
currently used in combination with other DAA in various 
countries[16].
DAA therapy in patients with cirrhosis
Although characterized by ground-breaking results, 
recent trials have underrepresented the populations 
traditionally associated with poorer treatment 
outcomes, including patients with advanced liver 
fibrosis. Nevertheless, encouraging results seem to 
emerge from reports comprising “real world” data 
collected from several institutions. Table 2 summarizes 
the outcome of the most representative clinical trials 
including cirrhotic patients treated with DAA.
SVR > 50% have been reported among cirrhotic 
patients treated with SOF/RBV although, in genotype 
3 patients receiving 12-wk regimens, cirrhosis was 
associated with limited responses[33,42]. LDV/SOF, with 
or without RBV (± RBV), has shown excellent SVR 
and low adverse effects in patients with cirrhosis[43,44]. 
A post-hoc analysis of data from seven clinical trials 
including 513 patients with genotype 1 HCV and 
compensated cirrhosis receiving LDV/SOF for 12 or 
24 wk ± RBV showed SVR12 of 98% and 95% for 
treatment-naïve and previously treated patients, 
respectively. Results were similar in patients receiving 
RBV compared to RBV-free regimens, except 
among previously treated patients who showed the 
lowest SVR (90%) in the arm without RBV. SAE and 
discontinuation rates were in the range of 1%-2%[45]. 
Recently, the results of SOF/SMV ± RBV regimens 
in a heterogeneous cohort of 995 patients including 
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Table 1  Expected benefits of new treatments for hepatitis C virus infection
Target population Main objectives Outcome
General population with chronic 
HCV infection
Achieve excellent SVR rates for all genotypes, reduce side effects, 
shorten treatment duration, simplify regimen schedules
Reduced ESLD incidence and indication for 
LT 
Patients on LT waiting list Achieve pre-transplant undetectable HCV-RNA; improve MELD 
scores
Reduced post-LT HCV recurrence; improved 
clinical conditions
Recipients of LT with HCV recurrence Increase SVR rates, reduce side effects and dropouts, decrease 
drug-drug interactions, simplify regimen schedules
Increased patients and grafts survival
HIV/HCV-coinfected patients and 
coinfected LT recipients
Increase SVR rates, reduce side effects and dropouts, decrease 
drug-drug interactions, simplify regimen schedules
Increased patients and grafts survival
HCV: Hepatitis C virus; SVR: Sustained virological response; ESLD: End stage liver disease; LT: Liver transplant; MELD: Model for end-stage liver disease; 
HIV: Human immunodeficiency virus.
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100-fold greater than the mean pre-LT months around 
one year after LT[54]. Histologic progression of HCV 
during immunosuppressive therapy is more rapid 
than that in nontransplant patients, probably due 
to a compromised virus-specific T-helper subtype 1 
(TH1) CD4 immune response[55]. Liver biopsies are 
currently the most effective method to diagnose and 
differentiate HCV disease, showing good sensitivity 
starting from 3 mo after LT[51]. In earlier stages, 
histological differentiation between HCV disease, 
reperfusion injury, and rejection can be challenging. 
A small proportion of patients (4%-7%) develop 
fibrosing cholestatic hepatitis (FCH), an accelerated 
course of liver injury associated with very high levels 
of viremia, rapid allograft failure, and poor response to 
therapy due to direct cytotoxic damage favored by a 
lack of specific anti-HCV response along with increased 
TH2 cytokine expression[56]. Following graft infection, 
chronic HCV disease develops in 75% to 90% of 
patients. Evolution towards cirrhosis is reported 5% to 
30% of cases within 5 years and up to 40% within 10 
years compared to 20 years in the nontransplantation 
setting[57-59]. HCV-associated graft failure represents the 
most common cause of graft loss and patient mortality 
in HCV-infected recipients, occurring in approximately 
10% of LT recipients within 5 years[60]. Overall, survival 
of patients and grafts with recurrent post-LT HCV 
infection is lower compared to patients receiving LT 
for other indications[57,61]. Various risk factors have 
been associated with unfavorable outcomes in HCV-
infected recipients. Some of them, such as prolonged 
cold ischemia time, advanced donor age, CMV 
hepatitis, treatment for acute rejection (e.g., steroid 
bolus or monoclonal antibody OKT3), development 
of postoperative insulin resistance diabetes mellitus 
or metabolic syndrome are potentially modifiable and 
should be either carefully evaluated in the process of 
donor selection or monitored in the post-LT[10,62-64]. 
30% of patients with cirrhosis were compared with 
SOF/PEG/RBV and SOF/RBV[46]. In the group of 
patients with genotype 1 and previously treated 
for HCV, a significant difference in SVR was noted 
between patients without cirrhosis vs patients with 
cirrhosis, with better results for SOF/SIM ± RBV (84% 
vs 65%, respectively) compared to SOF/Peg-IFN/RBV 
(94% vs 80%, respectively). Overall, discontinuation 
rates around 5% were noted. Other promising DAA 
combinations include grazoprevir (MK-5172) and 
elbasvir (MK-8742), showing high SVR12 at 12 wk 
among patients with genotype 1 and cirrhosis with 
and without RBV (90% and 97%, respectively)[47]. 
MK-5172/MK-8742 combination has recently also 
been tested among patients with advanced chronic 
kidney disease, showing SVR12 of 99%[48]. The 3DAA 
combination of DCV with asunaprevir (NS3 protease 
inhibitor) and BMS-791325 (non-nucleoside NS5B 
inhibitor) was studied in patients with HCV genotype 
1 infection and compensated cirrhosis. SVR were 87% 
and 93% in experienced patients treated with and 
without RBV, respectively[49].
IMPACT OF RECURRENT HCV INFECTION 
AFTER LIVER TRANSPLANTATION
Patients showing detectable HCV-RNA levels at 
transplantation universally experience recurrent 
postoperative HCV infection[50]. Reinfection likely 
occurs during graft reperfusion via circulating virions 
or infected mononuclear cells, and it is documented as 
detection of HCV-RNA in serum or in the allograft itself. 
HCV-RNA can be present as early as 48 h post-LT, 
with expression of HCV antigens on the hepatocytes 
from postoperative day 10[51-53]. Post-transplant HCV 
kinetics has shown that serum HCV-RNA levels reach 
pre-LT titers usually within day 4, then increase 
and peak around month 3, attaining levels 10- to 
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Table 2  Sustained virological response among recent clinical trials of new treatment regimens for hepatitis C virus including patients 
with cirrhosis
Ref. Trial Population Drug Overall SVR12 SVR12 in cirrhosis
Jacobson et al[143], 2014 Fusion G2, G3 experienced SOF/RBV 12 vs 16 wk G2 86% vs 94% G2 60% vs 78%
34% cirrhotic G3 62% vs 30% G3 19% vs 61%
Lawitz et al[33], 2015 Fission G2, G3 naïve SOF/RBV 12 wk vs Peg-IFN/
RBV 24 wk
G2 97% vs 78% G2 92% vs 62%
20% cirrhosis G3 56% vs 63% G3 30% vs 34%
Jacobson et al[143], 2014 Positron G2, G3 naïve and experienced 
IFN ineligible
SOF/RBV G2 93%, G3 61% G2 92%, G3 21%
Zeuzem et al[144], 2014 Valence G3 extended 24 wk 21% cirrhosis SOF/RBV G2 94%, G3 91% G2 82%, G3 68%
Lawitz et al[42], 2015 Lonestar-2 G 2 and 3 SOF/RBV/Peg-IFN G2 96%, G3 83% G2 93%, G3 83%
Bourliere et al[43], 2015 Sirius G1 with compensated cirrhosis, 
NR previous treatment
SOF/LDV 24 wk vs SOF/
LDV/RBV 12 wk
N/A 97% vs 96%
Lawitz et al[36], 2014 Cosmos G1 NR, 52% F3-F4 SOF/SMV ± RBV 12 or 24 wk 92% 94%
Gane et al[114], 2014 Electron Ⅱ G1 naïve, experienced and 
decompensated, G3 naïve, 15% 
cirrhosis
LDV/RBV 12 wk G1 100%, G3 64% G1 65%
Peg-IFN: Pegylated interferon; RBV: Ribavirin; SVR12: Sustained virological response; G: Genotype; LDV: Ledipasvir; SOF: Sofosbuvir; SMV: Simeprevir; 
NR: Non responder.
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Other risk factors include high preoperative model 
for end-stage liver disease (MELD) score, fibrosis 
stage ≥ 2 at 12-mo biopsy, recipient IL28B TT 
genotype, and history of HCC[10,50,65-68]. Marked, 
transient hyperbilirubinemia has been associated with 
allograft cirrhosis in HCV-infected LT recipients[69]. 
Among virological factors, high pretransplantation 
HCV-RNA titers (> 1 mEq/mL) have been strongly 
related with severe recurrent HCV. Patients with lower 
pretransplantation HCV RNA had 5-year survival of 
84% compared to 57% of patients with higher HCV 
RNA titer (p < 0.0001)[70]. Interestingly, neither viral 
genotype nor elevated post-LT viral titers have been 
found to be reliable predictors of outcome. At best, the 
most effective way to prevent HCV recurrence is the 
eradication of HCV prior to LT.
ANTIVIRAL THERAPY IN RECURRENT 
HCV INFECTION
HCV infection treatment: Before or after liver 
transplantation?
The likelihood of SVR diminishes with increasing severity 
of liver disease. In patients with cirrhosis, SVR rates are 
reduced compared to non-cirrhotic patients, ranging 
between 40%-50% for Child-Turcotte-Pugh (CTP) 
class A and being as low as 7%-26% for CTP class C 
patients treated with Peg-IFN/RBV[17-19,71]. Genotype 1 
and 4 patients with cirrhosis showed lower treatment 
responses compared with genotype 2 and 3 patients 
(33% vs 57%, respectively)[71]. Factors such as poor 
tolerability, dose reductions, and therapy discontinuation 
have a significant impact on therapy outcomes in this 
patient population[72]. IFN-based treatment is generally 
poorly tolerated and can be associated with severe 
infections and liver decompensation; overall, up to a 
third of patients is reported to discontinue the treatment 
because of adverse events[72]. Nevertheless, the 
evidence that high HCV-RNA levels at transplantation 
correlate with rapid, clinically evident recurrence of 
post-transplantation HCV disease supports the attempt 
of an aggressive pre-transplantation treatment[10]. 
IFN is contraindicated in patients with decompensated 
cirrhosis; selected patients listed for LT showing compen-
sated or mildly decompensated liver disease, however, 
have been previously considered for treatment with 
Peg-IFN/RBV ± TPV or BOC. A significant portion of LT 
candidate often present advanced ESLD or absolute 
contraindications to IFN-based therapy, requiring to 
delay HCV treatment after transplant. With the recent 
introduction of new DAA, successful treatment of 
patients on transplant waiting list seems possible. In this 
group, a reduction in MELD score caused by the positive 
impact of the treatment on liver decompensation 
can potentially lead to patient delisting, therefore 
lowering the proportion of waiting list registrants for 
transplantation due to HCV-related ESLD. 
Post-LT treatment is generally started following the 
12-mo liver biopsy if histologic severity reaches grade 
3 or 4 inflammation or stage 2 or higher of fibrosis. 
Irrespective of grade and stage, cholestatic hepatitis 
is usually an indication for treatment[10]. Treatment of 
post-LT recurrent HCV disease is limited by moderate 
SVR, potential drug-drug interactions, and toxicity. In 
this cohort, as in the pre-transplant group, new anti-
HCV therapies can provide substantial improvements 
in terms of efficacy and safety. Aims, advantages and 
disadvantages of the pre-LT and post-LT approaches 
are reported in Table 3.
Treatment before liver transplantation
The treatment of patients with decompensated 
cirrhosis is problematic due to coexisting leukopenia, 
thrombocytopenia, and other manifestations of ESLD 
that cause poor drug tolerance, often requiring the use 
of grow factors and transfusions[73]. In the registration 
trials for Peg-IFN/RBV, SVR rates were 5% to 15% 
lower in patients with advanced fibrosis or cirrhosis 
compared to patients who did not present advanced 
liver disease[17,18]. Various non-randomized studies 
have investigated the efficacy of diverse IFN or Peg-
IFN-based regimens in HCV-infected patients candidate 
to LT (Table 4). A study using increasing doses of IFN 
and RBV based on tolerability demonstrated SVR only 
in 13% of patients with HCV genotype 1. Predictors 
of SVR were non-1 genotype, CTP class A for patients 
with genotype 1, and ability to tolerate full dose and 
treatment completion[74]. Other reports showed rates 
of HCV-RNA suppression in patients with advanced 
liver disease around 20%-30%[75-78]. More recently, 
Everson et al[79] conducted a randomized, controlled 
trial to test the efficacy and safety of Peg-IFN/RBV, 
both escalated as tolerated, to prevent post-transplant 
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Table 3  Pros and cons of hepatitis C virus treatment before and after liver transplant
Before LT After LT
Aim Prevention of HCV recurrence Treatment of HCV recurrence
Advantages Undetectable HCV-RNA at transplantation correlates with low rates of post-LT HCV 
recurrence
Increased tolerance to treatment
Disadvantages Low eligibility due to compromised baseline conditions High rates of adverse effects
High rates of serious side effects and discontinuation rates Moderate SVR rates
Low SVR rates Drug-drug interactions
HCV: Hepatitis C virus; LT: Liver transplant; SVR: Sustained virological response.
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HCV recurrence in patients listed for LT. Overall, 
22% of patients with genotype 1, 4 or 6 and 29% of 
patients with genotype 2 or 3 obtained SVR12. Among 
patients completing at least 16 wk of treatment, 
SVR rates reached 50%. In conclusion, IFN-based 
regimens obtained poor SVR among patients listed for 
LT, mainly due to an intrinsic reduced response along 
with a low rate of treatment completion. DAA triple 
therapy showed increased SVR in a study including 29 
patients with low MELD scores but high rates (66%) 
of prior non-responders. The majority of patients were 
treated with Peg-IFN/RBV/TVR. Patients on waiting list 
had SVR of 41% and patients undergoing LT showed 
SVR of 67%. Despite demonstrating considerably 
higher SVR rates compared to Peg-IFN/RBV, the 
use of BOC or TPV was associated with increased 
SAE and a high pill burden[11]. As shown in Table 4, 
encouraging results have been displayed by IFN-free 
HCV regimens. Osinusi et al[80] administered SOF in 
combination with either weight-based (n = 24) or low-
dose (600 mg daily) RBV for 24 wk to 28 genotype 1 
patients, including those with advanced fibrosis. SOF/
RBV combination resulted in 50% and 29% SVR in 
weight-based and low-dose RBV groups, respectively 
(difference not significant). Advanced liver fibrosis and 
high HCV RNA at baseline were identified as predictors 
of relapse. Neither discontinuation nor SAE were 
registered. SOF/RBV combination was also used in a 
phase 2 study to treat 61 patients (73% with genotype 
1 and 75% previously treated for HCV) waitlisted to 
undergo LT for HCC. Overall, 49% of treated patients 
has post-LT SVR; among those who had undetectable 
HCV-RNA at transplantation, 70% achieve SVR[81]. 
A number of days of undetectable HCV RNA level 
pretransplant > 30 was significantly associated with 
SVR12. 
IFN-free, DAA combination therapies have shown 
the highest rates of SVR among patients with advanced 
liver disease previously treated for HCV. Cure rates 
close to 90% in patients with decompensated cirrhosis 
were reported among 108 patients receiving LDV/
SOF/RBV for 12 or 24 wk[82]. Of note, a substantial 
improvement of liver synthesis function of the patients 
with successful HCV therapy was documented by an 
improvement in MELD score. Nevertheless, despite 
achieving SVR, liver disease continued to progress in 
some patients. Although no current data is available 
in patients with decompensated cirrhosis treated with 
LDV/SOF without RBV, promising results have been 
achieved in patients with compensated cirrhosis, 
including those previously treated with SOF[83,84].
Various IFN-free, DAA combination trials are 
currently ongoing in patients with decompensated 
cirrhosis[85,86]. A recent trial included patients with 
advanced cirrhosis and post-liver transplant HCV 
recurrence treated with DCV/SOF/RBV for 12 wk. In 
the cirrhosis cohort, genotype 1 patients achieved 
overall SVR of 82% (92%, 91% and 50% in CTP A, B, 
and C, respectively[87].
Current recommendations for the treatment of 
LT candidates with decompensated cirrhosis include 
LDV/SOF/RBV for genotype 1 administered for 12 wk 
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Table 4  Outcome of pre-transplant hepatitis C virus therapy in studies with different regimens
Ref. Population n Treatment regimen Outcome Adverse effects
Everson et al[74], 2005 63% decompensated 
cirrhosis  (MELD 11 ± 3.7)
124 IFN (5 MU 3/wk) or Peg-IFN (0.75 
μg/kg per week)/RBV (600 mg/d 
escalated)
SVR 13% (G1), 
50% (other genotypes) 53% 
relapse 29% completed 
course
13% discontinuations 
and SAE (2 deaths)
Crippin et al[75], 2002 LT waiting list   15 IFN (3 MU 3/wk or 1 MU/d) ± RBV 
400 bid
SVR 33% 1.3 SAE/patient 
(one death)
Forns et al[145], 2003 LT waiting list   30 IFN (3 MU/d)/RBV 800 mg/d SVR 20% 
(3 relapse after LT)
63% dose reduction
Thomas et al[76], 2003 LT waiting list   21 IFN (5 MU/d) SVR 20% 
(8 relapse after LT)
No SAE
Carrión et al[78], 2009 LT waiting list   51 Peg-IFN/RBV SVR 20% 39% bacterial infections
Everson et al[79], 2013 LT waiting list   59 Peg-IFN/RBV 
(from 0.75 μg/kg per week and 600 
mg/d escalated)
SVR12 22% (G 1-4), 
29% (G 2-3), 
50% if > 16 wk
68% 
(2.7 SAE/patient)
Verna et al[11], 2015 LT waiting list   29 PI-based triple therapy 
(93% TVR, 7% BOC)
SVR 52% 31% SAE; one death 
28% hospitalizations
Curry et al[81], 2015 LT waiting list for HCC 
(CTP < 7) 
  43 Sofosbuvir 400/d plus RBV 
1000-1200 up to 48 wk




Charlton et al[82], 2015 Decompensated cirrhosis 108 LDV/SOF/RBV (600 mg/d 
escalating) 12 vs 24 wk
SVR 87% vs 89%, 
CTP B 87% vs 89%, 
CTP C 86% vs 87%
26% SAE 
3 discontinuation
Poordad et al[85], 2015 Advanced cirrhosis 
(70% CTP B-C)
  60 DCV/SOF/RBV 12 wk SVR 83%, CTP A 91%, CTP 
B 92%, CTP C 50%
No SAE
LT: Liver transplant; HCC: Hepatocellular carcinoma; CTP: Child-Turcotte-Pugh; IFN: Interferon; Peg-IFN: Pegylated interferon; RBV: Ribavirin; SVR: 
Sustained virological response; G: Genotype; SAE: Serious adverse effects; MELD: Model for End-Stage Liver Disease; PI: Protease inhibitor; TVR: 
Telaprevir; BOC: Boceprevir; LDV: Ledipasvir; SOF: Sofosbuvir; DCV: Daclatasvir.
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(or 24 wk if RBV intolerant or previous SOF therapy), 
SOF/RBV for 48 wk in genotypes 2 and 3 and DCV/
SOF/RBV for 12 wk for all genotypes[16,85].
HCV treatment after LT
The achievement of SVR in recurrent HCV infection 
after LT is associated with stabilization of fibrosis and 
improved graft survival. In this setting, however, poor 
therapy tolerability represents an important limitation. 
Some studies have explored the effects of early or 
pre-emptive treatment, starting anti-HCV therapy 
immediately after LT in patients who may tolerate it, 
such as HCC patients with low MELD[88]. The rationale 
for this approach is to act at a time when HCV-RNA is 
low and histologic damage is virtually absent[89]. Among 
living donor recipients, in particular, the treatment 
could be easily planned and has shown encouraging 
results[88]. Overall, the success of this strategy was 
limited by low SVR and high rates of discontinuation, 
while the effective impact on patients’ survival has not 
been clearly proven[90,91]. In the treatment of clinically 
evident disease, non-controlled studies including 
patients with recurrent HCV infection showed SVR 
rates ranging from 26% to 50% for Peg-IFN/RBV 
therapy (Table 5)[92-101]. When initiated at the early 
stages of HCV recurrence (F0-F2), an advantage of 
Peg-IFN/RBV treatment was demonstrated, showing 
SVR around 50%; however, the possible increased 
risk of rejection was not defined[77]. Similarly to 
nontransplant patients, factors associated with SVR 
among LTR included low pretreatment HCV RNA levels, 
absence of advanced cirrhosis, having a genotype 
other than 1, and early virological response[93]. A 
systematic review encompassing 38 studies showed 
overall SVR of 24% for standard IFN and 27% for 
Peg-IFN/RBV, with discontinuation rates of 24% and 
26%, respectively[102]. Similarly to LT candidates, PI-
based triple therapy in HCV-infected LT recipients was 
initially deemed as a combination that would have 
drastically increased the rates of SVR. Nevertheless, 
this treatment did not meet the expectations, showing 
suboptimal efficacy counterbalanced by high SAE rates 
and challenges in managing drug-drug interactions 
between PI and calcineurin inhibitors (CNI), particularly 
tacrolimus[103-106]. Overall, anemia, infection rates, and 
liver decompensation have significantly limited this 
therapeutic approach in LTR[107-109].
2014 AASLD recommendations
A multicenter study has shown SVR of 70% among 
40 LTR with compensated HCV disease treated with 
SOF/RBV for 24 wk[110]. There were no deaths, graft 
losses or episodes of liver decompensation among 
post-liver transplantation patients, and no drug-
drug interactions were reported between SOF and 
immunosuppressive agents. Among 92 patients with 
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Table 5  Anti-hepatitis C virus therapy in liver transplant recipients with recurrent hepatitis C virus infection: Outcome of main 
studies from the past 10 years
Ref. Population n Treatment regimen SVR Adverse effects
Interferon (IFN) or pegylated interferon (Peg-IFN) plus ribavirin (RBV) regimens
   Fernández et al[95], 2006 LTR with recurrent HCV   47 Peg-IFN/RBV 23% 21% SAE
   Carrión et al[77], 2008 LTR with mild recurrence (F0-F2)   27 Peg-IFN/RBV 48% 56% discontinuation
   Berenguer et al[92], 2008 LTR with recurrent HCV   89 IFN/RBV vs Peg-IFN/RBV 16% vs 48% 20% decompensation; 
15% deaths
   Hanouneh et al[93], 2008 LTR with recurrent HCV   53 Peg-IFN/RBV 35% 23% SAE
   Ueda et al[146], 2010 LTR with recurrent HCV (G1)   34 Peg-IFN alfa-2b + RBV 50% 18% discontinuation
DAA triple therapy with Peg-IFN/RBV plus boceprevir (BOC) or telaprevir (TVR)
   Verna et al[109], 2015 Advanced fibrosis (F > 3) and 9 
FCH
  49 Peg-IFN/RBV/TVR or 
BOC
51% AF 44% CH 22% AF and 33% CH 
decompensation 
   Pungpapong et al[108], 2013 LTR with recurrent HCV   60 Peg-IFN/RBV/TVR (35) 
or BOC (25)
67% TVR 45% BOC 12% decompensation, 
2 deaths
   Coilly et al[107], 2014 LTR with recurrent HCV   37 Peg-IFN/RBV/TVR (19) 
or BOC (18)
20% TVR 71% BOC 14% SAE, 27% infection, 
3 deaths
IFN-free DAA regimens
   Forns et al[111], 2015 Post-LT decompensated 
cirrhosis and FCH
  92 SOF/RBV ± Peg-IFN 24-48 
wk
59% 46% SAE
   Charlton et al[110], 2015 LTR with recurrent HCV   40 SOF/RBV 24 wk 70% No SAE
   Reddy et al[44], 2015 Post LT recurrence 
(121 CPT B and C)
223 LDV/SOF/RBV 12 vs 24 
wk
94% (60% CTP C) 4% SAE, 
3% discontinuation
   Gutierrez et al[118], 2015 Post LT recurrence   61 SOF/SMV ± RBV 93% No SAE
   Pungpapong et al[119], 2015 Post LT recurrence 123 SOF/SMV ± RBV 90% 1 death possibly related to 
treatment
   Kwo et al[103], 2014 Post LT recurrence (G1)   34 Paritaprevir/r/Ombitasvir 
and Dasabuvir/RBV
97% 1 discontinuation
   Poordad et al[85], 2015 Post LT recurrence   53 DCV/SOF/RBV 12 wk 94% 1 discontinuation (SVR); 
no SAE
LTR: Liver transplant recipients; SVR: Sustained virological response; CTP: Child-Turcotte-Pugh; SAE: Serious adverse event; FCH: Fibrosing cholestatic 
hepatitis; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; r: Ritonavir; DCV: Daclatasvir.
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severe HCV disease, including liver decompensation, 
SOF compassionate use program (in association with 
RBV ± Peg-IFN) showed SVR12 of 59%; higher SVR 
(73%) were shown in patients treated for early severe 
recurrence[111]. Based on these results, combination 
treatments containing SOF are currently included 
in the 2014 AASLD recommendations for patients 
who develop recurrent HCV infection post-LT (Table 
6)[112]. DAA combination therapy with LDP/SOF/RBV is 
indicated for patients with genotype 1 and 4, including 
those previously treated for HCV and patients with 
decompensated cirrhosis (with reduced RBV dose). 
The efficacy of this regimen was assessed in a large, 
multicenter, randomized controlled trial showing high 
rates of SVR irrespective of the treatment duration (12 
wk vs 24 wk) along with improvements in MELD score, 
albumin and bilirubin[113]. The study included 223 LTR 
with a wide spectrum of histologic and clinical severity 
of HCV recurrence. Thirty-seven/44 (84%) CTP B and 
5/8 (63%) CTP C patients achieved SVR12, compared 
to 97% of patients with F0-F2 and compensated 
cirrhosis. Overall, 8 treatment-related SAE were 
documented. CTP C patients appeared to have lower 
SVR compared to the other groups, although the 
number of patients in this group was limited. Although 
its importance cannot be ascertained, the addition of 
RBV could have been responsible for the high SVR12 
rates observed. According to the AASLD guidelines, 
a 24-wk course of LDP/SOF is recommended in LTR 
that are intolerant or ineligible to receive RBV. Patients 
with genotype 3 including cirrhotic patients, however, 
have shown suboptimal responses, especially with 
12-wk regimens (Table 2). A 24-wk course of SOF/RBV 
is recommended in patients with genotype 3 with 
recurrent post-LT HCV disease (Table 6). Indications on 
the use of LDP/SOF for genotype 3 LTR are not made 
due to a lack of data in the post-LT setting and limited 
data among patients with cirrhosis. Nevertheless, 
a phase Ⅱ study has reported SVR 12 of 100% for 
LDP/SOF/RBV compared to 64% for LDP/SOF in a 
cohort of patients with G3 infection (including 15% 
cirrhotic), potentially suggesting that LDV could even 
shorten the treatment duration in this group[114]. A 
limitation in the use of LDV regards the concomitant 
use of proton pump inhibitors, that attenuate its 
absorption by > 90%. Promising results in LTR were 
also shown with the pan-genotypic combination of 
DCV/SOF/RBV. Analysis from a small group of 12 
LTR showed SVR of 75% along with absence of drug-
drug interactions and SAE[115]. A study presented at 
the 2014 AASLD meeting including patients from 
the same cohort showed CTP score improvements 
in 20 patients (from 7.3 to 5.8, p = 0.004)[116]. More 
recently, the results of the phase 3 ALLY-1 trial in 
LTR treated with DCV/SOF/RBV reported overall SVR 
of 94% regardless of prior treatment experience[86]. 
Treatment with DCV/SOF/RBV has been included in 
the 2015 EASL (European Association for the Study of 
the Liver) recommendations for the treatment of HCV 
recurrence, including decompensated cirrhosis, in all 
genotypes[16].
A multicenter study including 34 LTR with mild 
genotype 1 HCV recurrence (F0-F2) treated with 
paritaprevir/ritonavir, ombitasvir, twice-daily dosed 
dasabuvir, and RBV for 24 wk showed overall SVR 
of 97%[103,117]. Dose adjustments were needed for 
cyclosporine and tacrolimus due to interactions 
between ritonavir and CNI. Only one discontinuation 
in a patient who achieved SVR was noted. Since the 
efficacy and tolerability in patients with more advanced 
HCV infection are not well known, this regimen is 
currently only recommended for LTR without cirrhosis. 
The association of SMV/SOF ± RBV is suggested as an 
alternative regimen in genotype 1 patients without liver 
decompensation and recurrent HCV disease post-LT. 
A retrospective analysis of a single center involving 
61 patients with HCV genotype 1 infection who 
received a 12-wk combination regimen of SOF/SMV 
post-LT showed SVR12 of 93% compared with 67% in 
patients with advanced fibrosis[118]. No SAE occurred 
during treatment. Similar results were obtained in a 
large multicenter study encompassing 123 patients 
receiving SOF/SMV after a median time from LT of 
32 mo. SVR12 was achieved in 90% of patients, 
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Table 6  American Association for the Study of Liver Diseases 2014 recommendations for therapy in recurrent hepatitis C virus 
post liver transplant
Rating Population CPT B and C Regimen Daily Dose
ⅠB-recommended G 1, 4 experienced and naïve RBV 600 mg, increased as tolerated1 LDV/SOF/RBV 12 wk 90 mg/400 mg/weight-based2
ⅠB-alternative G 1, 4 naïve, RBV intolerant Not recommended LDV/SOF 24 wk 90 mg/400 mg
ⅠB-alternative G1 Not recommended SOF/SMV ± RBV 12 wk 400 mg + 150 mg ± weight-based2
ⅠB-alternative G1 Recommended only for non-
cirrhosis
Paritaprevir/r/rombitasvir/
dasabuvir + RBV for 24 wk
150 mg/100 mg/25 mg/250 mg 
bid/weight-based2
ⅡB-recommended G2 experienced and naïve 600 mg/d, SOF/RBV 24 wk 400 mg/weight-based2
increased as tolerated1
ⅠB-recommended G3 experienced and naïve 600 mg, increased as tolerated1 SOF/RBV 24 wk 400 mg/weight-based2
ⅢA Not recommended: Regimens containing PEG-IFN, monotherapy with PEG-IFN, RBV, or a DAA; TVR or BOC-based regimens
1e.g., increased monthly by 200 mg/d; 21000 mg < 75 kg, 1200 mg > 75 kg. Recommendations are graded according the level of the evidence and strength of 
the recommendation. G: Genotype; RBV: Ribavirin; LDV: Ledipasvir; SOF: Sofosbuvir; RBV: Ribavirin; r: Ritonavir; DCV: Daclatasvir; DAA: Direct active 
antiviral; TVR: Telaprevir; BOC: Boceprevir. 
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with rates around 70% in patients with advanced 
fibrosis[119]. While non-significant changes have been 
reported with tacrolimus use, up to 6-fold increases in 
SMV concentration have been noted in association with 
cyclosporine, due to inhibition of cytochrome P450 
3A, ion-transporting polypeptide, and p-glycoprotein. 
Based on this data, SMV/SOF is preferred in patients 
receiving tacrolimus and represents a valid option in 
patients with impaired renal function or anemia who 
may not tolerate RBV. Additional data on SIM/SOF 
± RBV came from a subgroup of 143 LTR from the 
TARGET cohort including 57% patients with cirrhosis. 
SVR4 rates were 94% among non-cirrhotic patients 
and 86% in patients with cirrhosis, showing a high 
level of concordance between cure rates obtained from 
clinical trials vs from real-life observational cohorts[120]. 
Treatment of LTR with Human immunodeficiency virus/
HCV coinfection
After the introduction of highly active antiretroviral 
therapy, ESLD has become the main cause of death 
among human immunodeficiency virus (HIV)/HCV-
coinfected patients[121]. In patients that are not 
successfully treated for HCV, HIV infection accelerates 
the course of liver disease and increases the mortality 
rate[122]. LT is an effective treatment for HIV/HCV-
coinfected patients with severe liver disease; LTR, 
however, display significantly lower survival rates 
(around 55% at 5 years) compared with HCV-
monoinfected patients[123]. HIV infection alone has a 
minor impact on the outcome of organ transplantation; 
in fact, excellent results are reported among HIV 
monoinfected (or HIV/HBV-coinfected) patients 
undergoing LT, and better outcomes for HIV-positive 
compared to HCV-infected recipients of organ 
transplant have been recently demonstrated[124]. 
HIV/HCV coinfection, however, accelerates post-LT 
progression towards fibrosis and liver decompen-
sation[125]. Furthermore, interactions between immuno-
suppressants and antiretrovirals via modulation of 
cytochrome P450 contribute to higher rates of acute 
graft rejections compared to non-HIV infected patients. 
Although new classes of antiretrovirals with limited 
interactions, such as integrase inhibitors and CCR5 
receptor antagonist, are currently used in HIV/HCV-
coinfected LTR, the presence of multiple and reciprocal 
drug-drug interactions or pathological conditions can 
still affect plasma drug concentrations[126,127]. Moreover, 
HIV/HCV-coinfected patients have historically shown 
high adverse effects and discontinuation rates following 
anti-HCV treatment[128,129]. Overall, poor survival along 
with limited effective therapeutic options still represent 
major barriers to LT in this cohort[130,131]. Data reporting 
the results of anti-HCV treatment in HIV/HCV-
coinfected LTR is scarce. Responses to Peg-IFN/RBV 
were significantly lower in HCV/HIV-coinfected LTR 
compared to monoinfected transplant recipents (10% 
vs 33%, respectively), particularly among genotype 1 
patients[129]. Nevertheless, HIV/HCV-coinfected patients 
achieving SVR showed survival rates up to 79%. The 
use of BOC and TVR in 7 HIV/HCV-coinfected LTR with 
severe HCV recurrence demonstrated 60% SVR and no 
response, respectively, along with high rates of SAE[132]. 
Preliminary results on SOF/RBV compassionate use, 
instead, showed SVR4 of 100% and good tolerability in 
7 HIV/HCV-coinfected LTR[133]. 
Thanks to an improved efficacy, safety, and 
tolerability in HIV and transplant patients, the newly 
approved antiviral therapies have the potential to 
transform the treatment outcomes of HIV/HCV-
coinfected patients with liver complications. Data from 
nontransplant patients suggests that HIV infection itself 
does not negatively impact SVR. Two trials involved 
a heterogeneous population of HIV/HCV-coinfected 
patients treated with SOF/RBV including different 
genotypes, patients with compensated cirrhosis, and 
treatment experienced patients. SVR12 were 90% 
in genotype 2 (irrespective of treatment duration) 
and above 80% among the other genotypes[129,134]. 
High relapse rates in genotype 1 patients, however, 
suggested that dual DAA combinations is preferred 
in this group; overall, lowest SVR were displayed 
in patients with genotype 3 treated for 12 wk and 
in patients with genotype 1 and cirrhosis. Therapy 
duration of 12 wk for genotype 2 and 24 wk for 
genotype 3 and 4 are recommended. Low rates of SAE 
and discontinuation (8% and 2.5%, respectively) were 
reported. Other key studies in this cohort included 
the combination of SOF/LDV administered for 12 wk 
to 50 GT1 coinfected patients with optimal baseline 
conditions (e.g., absence of cirrhosis or previous 
treatment failures) showing SVR rates close to 
100%[135]. The same combination showed SVR rates of 
94% and 97% in cirrhotic and treatment-experienced 
patients, respectively, in a study encompassing 335 
coinfected HIV-HCV patients[136]. 
In a trial including 20% of patients with cirrhosis, 
HIV/HCV-coinfected patients receiving paritaprevir/
r/ombitasvir, dasabuvir and RBV had SVR rates 
above 90%, irrespective of treatment duration[137]. 
Combination of grazoprevir and elbasvir showed 
comparable results between monoinfected and 
coinfected subjects (SVR12 of 93% vs 97% with RBV 
and 98% vs 87% without RBV, respectively)[138]. Data 
on SMV use in coinfected patients is limited; its use in 
12 HIV/HCV-positive patients showed SVR of 92%[139].
DCV/SOF regimens in HIV/HCV-coinfected patients 
showed SVR of 98% when administered for 12 wk 
in treatment-experienced patients. Shorter regimens 
(e.g., 8 wk), however, were associated with high 
relapse rates especially in cirrhotic patients[140].
Although some trials were limited by a small number 
of patients or presented only interim results, anti-HCV 
treatment appeared to have similar efficacy among 
coinfected and monoinfected patients. Therefore, the 
new guidelines do not consider HIV/HCV coinfected 
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patients as a special population and recommend DAA-
based treatments irrespective of HIV status. Among 
different anti-HCV regimens, paritaprevir/ritonavir/
ombitasvir plus dasabuvir was the most susceptible 
to drug interactions with antiretrovirals. SMV can also 
cause drug interactions with PI, efavirenz, etravirine, 
and ciclosporin; conversely, minor or non-clinically 
significant interactions were seen with DCV, SOF, or 
LDV[141]. LDV/SOF, however, may increase tenofovir 
levels when associated with ritonavir-boosted HIV 
PI and its use is not recommended in patients with 
estimated CrCl < 60 mL/min.
Recently, recommendations for the treatment of 
HIV/HCV-coinfected LTR with recurrent HCV disease 
have been published by a group of experts[142]. 
Based on the efficacy and the low potential for drug 
interactions, SOF/RBV and SOF/daclatasvir ± RBV 
were identified as potentially preferred regimens in 
HIV/HCV-coinfected LTR[142].
Updated databases and publications detailing the 
interactions between anti-HCV regimens and antire-
trovirals are available and should always be consulted 
for the management of coinfected patients[112,116].
CONCLUSION
Until recently, a well-tolerated and effective treatment 
protocol for the recurrence of HCV infection following 
LT has been an important unmet clinical need. The 
excellent response rates from new DAA combination 
therapies have opened new scenarios for patients 
with HCV-related advanced liver disease. Difficult-to-
treat patients (including LT candidates and recipients), 
however, have been understudied in recent trials. Even 
if data is limited in these patient populations, overall 
cure rates in clinical practice compared to clinical 
trials remained high, suggesting that even in real-life 
patients the high SVR rates can be reproducible. The 
benefits provided by the new anti-HCV regimens apply 
to both pre-transplant and post-transplant periods. 
Good safety profiles, high SVR rates, and MELD score 
improvement among patients with CTP C cirrhosis 
on waiting list shown by SOF-based regimens may 
lead to a delay in organ allocation. This result was not 
reported with Peg-IFN/RBV and could be attributed 
to IFN-free regimes that lack the catabolic effects 
induced by IFN, hence allowing a significant clinical 
improvement over a short time frame. Among LTR, 
early antiviral treatment after transplant (e.g., from 
6 to 12 mo) may become standard and reduce the 
occurrence of advanced CPT scores that have been 
correlated to a limited response to anti-HCV treatment. 
IFN-free, DAA combinations may represent the future 
ideal option for patients on transplant waiting list and 
post-LT. Given that a high proportion of patients in 
recent trials still required concomitant erythropoietin 
or blood transfusions, the possibility to eliminate RVB 
appears very attractive. Nevertheless, drawbacks 
and open questions still apply to the scenario of new 
anti-HCV drugs. While compounds such as SOF, 
GS-5816, and daclatasvir have activity against various 
genotypes, most combinations are mainly active 
against genotype 1. Among patients with genotype 3 
and cirrhosis, however, reduced SVR were reported. 
Furthermore, a growing number of patients who have 
failed under DAA-based therapy will need more potent 
treatment options in the near future. Specifically, 
cirrhotic genotype 1 patients with a history of previous 
HCV treatment failure represent a challenging 
population. Among patients with cirrhosis, including 
LTR, unanswered questions concern the need for RBV 
association to new therapies and the requirement to 
pursue longer treatment duration (12 wk vs 24 wk). 
Renal impairment, that often complicates ESLD, has 
not been fully addressed in the recent studies and 
necessitates further attention. Overall, a proportion 
of patients with advanced liver disease will progress 
towards ESLD despite the achievement of SVR, and the 
impact of new therapies is likely to be limited among 
patients with HCC. Finally, availability restrictions along 
with new treatments high cost still have a big impact 
on patient populations who necessitate prioritized 
treatment. 
In conclusion, the availability of new options in the 
treatment of HCV infection is likely to have a major 
impact in liver transplant candidates and recipients. 
Further studies employing new DAA combinations 
in the treatment of patients with decompensated 
cirrhosis, HIV/HCV coinfection, and chronic kidney 
disease are awaited in order to improve the manage-
ment of difficult-to-treat populations that often require 
urgent treatment.
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